Phase 1 clinical trials involving pancreatic cancer patients to evaluate the combination of a DNMTi with chemotherapy and/or PD-1/PD-L1 blockade are currently recruiting (NCT03257761, NCT01845805, NCT02959164). The gene discussed is CD274; the disease is familial pancreatic carcinoma.